Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board: Benjeddou, Mongi / Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Hirata, Rosario / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van der Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Sadee, Wolfgang / Salazar, Luis A. / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie / Zanger, Ulrich M.

4 Issues per year

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.531
Source Normalized Impact per Paper (SNIP) 2017: 0.645

See all formats and pricing
More options …
Volume 33, Issue 1


Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy

Baraa Alghalyini
  • Department of Family Medicine, College of Medicine Alfaisal University, Riyadh, Kingdom of Saudi Arabia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Said El Shamieh
  • Corresponding author
  • Department of Medical Laboratory Sciences, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ali Salami
  • Rammal Hassan Rammal Research Laboratory, Physio-toxicity (PhyTox), Lebanese University, Faculty of Sciences (V), Nabatieh, Lebanon
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Sophie Visvikis Siest
  • UMR INSERM U1122; IGE-PCV ‘Interactions Gène-Environnement en Physiopathologie Cardiovasculaire’, Université de Lorraine, Nancy, France
  • Department of Internal Medicine and Geriatrics, CHU Technopôle Nancy-Brabois, Vandoeuvre-lès-Nancy, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hana M. Fakhoury
  • Corresponding author
  • Department of Biochemistry and Molecular Biology, College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Rajaa Fakhoury
  • Department of Medical Laboratory Sciences, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon
  • Department of Biochemistry and Molecular Biology, College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-02-08 | DOI: https://doi.org/10.1515/dmpt-2017-0030



Statin therapy used to lower cholesterol levels results in a substantial reduction in cardiovascular complications. Previous observations in different ethnic populations showed that rs2306283A>G, p.Asn130Asp and rs4149056T>C, p.Val174Ala in solute carrier organic anion transporter 1B1 (SLCO1B1) gene encoding the organic transporter protein may be responsible for statin uptake, thus explaining the majority of statin-associated symptoms. In addition to the genetic component, vitamin D (vit D) deficiency is common in Saudi Arabia and worldwide and may cause muscle dysfunction and ache. The aim of the present study was first to reveal an effect of vit D, rs2306283A>G, and rs4149056T>C and related haplotypes on statin-associated myopathy (SAM) and then to investigate a possible interaction between low vit D levels and the above-mentioned variants.


The genomic DNA obtained from 50 individuals diagnosed with hypercholesterolemia was genotyped using light SNiP hybridization probes.


Low vit D levels were associated with SAM (OR=3.6, p=0.03); however, CK levels, rs2306283A>G, and rs4149056T>C did not show any association. Interestingly, rs4149056T>C was interacting with vit D to influence SAM (p=0.02). Haplotype analysis showed that SLCO1B1 *1B and *15 were more prevalent in individuals with SAM (p=0.05). When stratified according to vit D levels, rs2306283A allele showed an increase in individuals having SAM along with low vit D (p=0.03).


Although preliminary, our results show an involvement of vit D and rs4149056T>C of SLCO1B1 in SAM.

Keywords: Kingdom of Saudi Arabia; SLCO1B1 gene polymorphisms; statin induced myopathy; vitamin D


  • 1.

    WHO. Cardiovascular diseases (CVDs). WHO fact sheet, 2017.Google Scholar

  • 2.

    Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014;11:72–4.CrossrefWeb of SciencePubMedGoogle Scholar

  • 3.

    Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J 2015;36:1012–22.CrossrefWeb of SciencePubMedGoogle Scholar

  • 4.

    Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res 2014;63:S327–34.PubMedGoogle Scholar

  • 5.

    Jacobs ET, Alberts DS, Foote JA, Green SB, Hollis BW, Yu Z, et al. Vitamin D insufficiency in southern Arizona. Am J Clin Nutr 2008;87:608–13.PubMedCrossrefGoogle Scholar

  • 6.

    Goldstein MR. Myopathy, statins, and vitamin D deficiency. Am J Cardiol 2007;100:1328.CrossrefWeb of SciencePubMedGoogle Scholar

  • 7.

    Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med 2000;160:1199–203.PubMedCrossrefGoogle Scholar

  • 8.

    Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18:401–8.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 9.

    Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153:11–6.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 10.

    Morioka TY, Lee AJ, Bertisch S, Buettner C. Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis 2015;238:77–82.CrossrefPubMedGoogle Scholar

  • 11.

    Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency – a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf) 2009;71:154–5.CrossrefPubMedGoogle Scholar

  • 12.

    Kurnik D, Hochman I, Vesterman-Landes J, Kenig T, Katzir I, Lomnicky Y, et al. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol (Oxf) 2012; 77:36–41.PubMedCrossrefGoogle Scholar

  • 13.

    Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014;24:4–15.PubMedCrossrefGoogle Scholar

  • 14.

    Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81:353–73.CrossrefPubMedGoogle Scholar

  • 15.

    Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429–45.PubMedCrossrefGoogle Scholar

  • 16.

    Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276:35669–75.CrossrefPubMedGoogle Scholar

  • 17.

    Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73:554–65.PubMedCrossrefGoogle Scholar

  • 18.

    Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008;359:789–99.PubMedCrossrefGoogle Scholar

  • 19.

    Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609–16.Web of ScienceCrossrefPubMedGoogle Scholar

  • 20.

    Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012;92:112–7.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 21.

    Hubáček JA, Dlouha D, Adamkova V, Zlatohlavek L, Viklicky O, Hruba P, et al. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit 2015;21:1454–9.CrossrefGoogle Scholar

  • 22.

    Jiang J, Tang Q, Feng J, Dai R, Wang Y, Yang Y, et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.Web of SciencePubMedCrossrefGoogle Scholar

  • 23.

    Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15:97–8.PubMedCrossrefGoogle Scholar

  • 24.

    Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006;22:1928–9.PubMedCrossrefGoogle Scholar

  • 25.

    Alsuwadia AO, Farag YM, Al Sayyari AA, Mousa DH, Alhejaili FF, Al-Harbi AS, et al. Prevalence of vitamin D deficiency in Saudi adults. Saudi Med J 2013;34:814–8.PubMedGoogle Scholar

  • 26.

    Nair R, Maseeh A. Vitamin D: the “sunshine” vitamin. J Pharmacol Pharmacother 2012;3:118–26.PubMedGoogle Scholar

  • 27.

    Riche KD, Arnall J, Rieser K, East HE, Riche DM. Impact of vitamin D status on statin-induced myopathy. J Clin Transl Endocrinol 2016;6:56–9.CrossrefPubMedGoogle Scholar

  • 28.

    Shabana MF, Mishriki AA, Issac MS, Bakhoum SW. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Mol Diagn Ther 2013;17:299–309.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 29.

    Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr 2013;5.Google Scholar

  • 30.

    Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681–90.CrossrefPubMedGoogle Scholar

  • 31.

    Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793–806.CrossrefPubMedGoogle Scholar

  • 32.

    Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005;78:342–50.CrossrefPubMedGoogle Scholar

  • 33.

    Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. J Am Med Assoc 2003;289:1681–90.CrossrefGoogle Scholar

  • 34.

    Gehani AA, Al-Hinai AT, Zubaid M, Almahmeed W, Hasani MR, Yusufali AH, et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. Eur J Prev Cardiol 2014;21:400–10.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 35.

    Zubaid M, Rashed WA, Almahmeed W, Al-Lawati J, Sulaiman K, Al-Motarreb A, et al. Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Acta Cardiol 2009;64:439–46.Web of SciencePubMedCrossrefGoogle Scholar

  • 36.

    Dai R, Feng J, Wang Y, Yang Y, Deng C, Tang X, et al. Association between SLCO1B1 521 TC and 388 AG polymorphisms and statins effectiveness: a meta-analysis. J Atheroscler Thromb 2015;22:796–815.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 37.

    Kanan RM, Al Saleh YM, Fakhoury HM, Adham M, Aljaser S, Tamimi W. Year-round vitamin D deficiency among Saudi female out-patients. Public Health Nutr 2013;16:544–8.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 38.

    Alfawaz H, Tamim H, Alharbi S, Aljaser S, Tamimi W. Vitamin D status among patients visiting a tertiary care center in Riyadh, Saudi Arabia: a retrospective review of 3475 cases. BMC Public Health 2014;14:159.Web of ScienceCrossrefPubMedGoogle Scholar

  • 39.

    Tuffaha M, El Bcheraoui C, Daoud F, Al Hussaini HA, Alamri F, Al Saeedi M, et al. Deficiencies under plenty of sun: vitamin D status among adults in the Kingdom of Saudi Arabia, 2013. N Am J Med Sci 2015;7:467–75.Web of SciencePubMedCrossrefGoogle Scholar

  • 40.

    Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, El-Kholie E, Yousef M, et al. Increased vitamin D supplementation recommended during summer season in the gulf region: a counterintuitive seasonal effect in vitamin D levels in adult, overweight and obese Middle Eastern residents. Clin Endocrinol (Oxf) 2012;76:346–50.CrossrefPubMedGoogle Scholar

About the article

aBaraa Alghalyini and Said El Shamieh contributed equally to this work.

Received: 2017-10-07

Accepted: 2018-01-04

Published Online: 2018-02-08

Published in Print: 2018-03-28

Author contributions: All the authors have accepted responsibility for the entire content of the submitted manuscript and approved submission.

Research funding: The present work was funded by an internal research grant (project number 0712017) from AlFaisal University, Ryadh, Kingdom of Saudi Arabia.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Drug Metabolism and Personalized Therapy, Volume 33, Issue 1, Pages 41–47, ISSN (Online) 2363-8915, ISSN (Print) 2363-8907, DOI: https://doi.org/10.1515/dmpt-2017-0030.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in